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MaBACKGROUND The classic cardiovascular complication of chronic obstructive pulmonary disease (COPD) is cor
pulmonale or right ventricular (RV) enlargement. Most studies of cor pulmonale were conducted decades ago.
OBJECTIVES This study sought to examine RV changes in contemporary COPD and emphysema using cardiac magnetic
resonance (CMR) imaging.
METHODS We performed a case-control study nested predominantly in 2 general population studies of 310 participants
with COPD and control subjects 50 to 79 years of age with $10 pack-years of smoking who were free of clinical car-
diovascular disease. RV volumes and mass were assessed using magnetic resonance imaging. COPD and COPD severity
were deﬁned according to standard spirometric criteria. The percentage of emphysema was deﬁned as the percentage
of lung regions <950 Hounsﬁeld units on full-lung computed tomography; emphysema subtypes were scored by
radiologists. Results were adjusted for age, race/ethnicity, sex, height, weight, smoking status, pack-years, systemic
hypertension, and sleep apnea.
RESULTS Right ventricular end-diastolic volume (RVEDV) was reduced in COPD compared with control
subjects (7.8 ml; 95% conﬁdence interval: 15.0 to 0.5 ml; p ¼ 0.04). Increasing severity of COPD was
associated with lower RVEDV (p ¼ 0.004) and lower RV stroke volume (p < 0.001). RV mass and ejection
fraction were similar between the groups. A greater percentage of emphysema also was associated with lower
RVEDV (p ¼ 0.005) and stroke volume (p < 0.001), as was the presence of centrilobular and paraseptal
emphysema.
CONCLUSIONS RV volumes are lower without signiﬁcant alterations in RV mass and ejection fraction in contemporary
COPD, and this reduction is related to the greater percentage of emphysema on computed tomography. (J Am Coll
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AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac
magnetic resonance
COPD = chronic obstructive
pulmonary disease
CT = computed tomography
FEV1 = forced expiratory
volume in 1 s
FVC = forced vital capacity
LV = left ventricular
RV = right ventricular
RVEDV = right ventricular
end-diastolic volume
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2001C hronic obstructive pulmonary disease(COPD), the third leading cause of death inthe United States (1), is deﬁned by acceler-
ated, age-related loss of lung function resulting in
incompletely reversible airway obstruction (2). Over-
lapping partially with COPD, pulmonary emphysema
is described as airspace enlargement distal to the ter-
minal bronchioles with destruction of their walls.
Hypoxic pulmonary vasoconstriction, hypercapnia,
acidosis, and pulmonary vascular remodeling in
COPD can all contribute to increased pulmonary
vascular resistance and greater right ventricular (RV)
afterload, resulting in cor pulmonale or RV hypertro-
phy and dilation (3).SEE PAGE 2010 RVEF = right ventricular
ion fractionCor pulmonale was once considered common in
COPD (4), with resting pulmonary hypertension seen
frequently and exertional pulmonary hypertension
occurring in as many as 58% of COPD patients without
resting pulmonary hypertension (5), both of which
contribute to increased RV mass and volume. How-
ever, the contemporary literature on cor pulmonale in
COPD is limited by small sample sizes of highly
selected patients, perhaps due to the difﬁculties in
assessing the right ventricle using transthoracic
echocardiography in COPD and performing cardiac
catheterization in large cohorts. Some of these small
studies demonstrated increased RV mass and RV
dysfunction in COPD (6), whereas others showed
reduced RV size and intrathoracic blood volumes
(7–13). Hence, changes in RV structure and function
in contemporary COPD remain poorly deﬁned.
Therefore, in the MESA (Multi-Ethnic Study of
Atherosclerosis) COPD study, we assessed RV mor-
phology in COPD and emphysema in COPD patients
and control subjects drawn predominantly from the
general population undergoing cardiac magnetic
resonance (CMR) imaging, the standard of reference
for noninvasively assessing the RV. Given our previ-
ous ﬁndings showing a small right ventricle in pa-
tients with emphysema and historical autopsy studies
(14–16), we hypothesized that COPD and a greater
percentage of emphysema-like lung on computed
tomography (CT) would be associated with lower RV
volumes.
METHODS
STUDY SAMPLE. Between 2009 and 2011, the MESA
COPD study enrolled participants with COPD
and normal control subjects predominantly from a
prospective population-based cohort study (MESA)
(17) and a lung cancer screening and emphysemaprogression study (EMCAP [Emphysema and
Cancer Action Project]) (18). Participants were
50 to 79 years of age with $10 pack-years of
smoking and without a clinical diagnosis of
coronary heart disease, heart failure, cere-
brovascular disease, asthma before 45 years
of age, other lung disease or cancer, previous
lung resection, stages IIIb to V kidney dis-
ease, allergy to gadolinium, claustrophobia,
metal in the body, pregnancy, or weight >300
lb. Recent COPD exacerbation was a tempo-
rary exclusion criterion. We selected all
eligible participants at 4 sites in the MESA
Lung Study (19) and oversampled partici-
pants with COPD or emphysema from the
remainder of MESA and EMCAP, in addition
to a small number from neither study.
Protocols were approved by the institutional re-
view boards of the participating institutions and the
National Heart, Lung, and Blood Institute. Written
informed consent was obtained from all participants.
PULMONARY FUNCTION TESTING. Spirometry was
conducted in accordance with American Thoracic
Society/European Respiratory Society guidelines (20)
before and after inhalation of albuterol. COPD was
deﬁned as a post-bronchodilator ratio of the forced
expiratory volume in 1 s (FEV1) to the forced vital
capacity (FVC) <0.70 (2). COPD severity was classi-
ﬁed as mild, FEV1 $80% predicted; moderate,
FEV1 $50% to 79% predicted; and severe, FEV1 <50%
predicted (21).
EMPHYSEMA. All participants underwent full-lung
CT scans on 64-slice helical scanners following the
MESA-Lung/SPIROMICS (Subpopulations and Inter-
mediate Outcome Measures in COPD Study) full-
inspiration protocol (22). The percentage of emphy-
sema was deﬁned using Apollo software (Vida Di-
agnostics, Coralville, Iowa) as the percentage of total
voxels within the lung ﬁeld that fell below 950
Hounsﬁeld units (23). In addition, the presence or
absence of emphysema and predominant emphysema
subtype was assessed visually on all CT scans by an
experienced thoracic radiologist using a standardized
protocol (24) blinded to other clinical information.
MAGNETIC RESONANCE IMAGING. The CMR proto-
col was that of the ﬁfth examination of MESA modi-
ﬁed to include assessment of the pulmonary
vasculature (25); the protocol and methods for inter-
pretation were previously reported (26,27). RV image
analysis was performed by 2 independent analysts,
who were unaware of other clinical information, us-
ing QMASS software version 4.2 (Medis, Leiden, the
Netherlands). Right ventricular end-diastolic volume
eject
TABLE 1 Clinical Characteristics of Participants Stratiﬁed by COPD Severity
COPD
Controls
(n ¼ 163)
Mild
(n ¼ 60)
Moderate
(n ¼ 67)
Severe
(n ¼ 20)
Age, yrs 67.57  6.75 69.35  9.64 67.40  7.78 67.85  6.83
Male 90 (55.21) 43 (71.67) 40 (59.70) 14 (70.00)
Race/ethnicity
White 71 (43.56) 40 (66.67) 39 (58.21) 15 (75.00)
African American 40 (24.54) 15 (25.00) 21 (31.34) 5 (25.00)
Chinese American 15 (9.20) 3 (5.00) 2 (2.99) 0 (0.0)
Hispanic 37 (22.70) 2 (3.33) 5 (7.46) 0 (0.0)
Educational attainment
High school degree or less 45 (27.61) 12 (20.00) 15 (22.39) 4 (20.00)
Some college or vocational school 54 (33.13) 14 (23.33) 16 (23.88) 7 (35.00)
College degree or above 65 (39.26) 34 (56.67) 36 (53.73) 9 (45.00)
Height, cm 167.06  9.48 171.91  7.97 170.03  9.64 170.12  10.40
Weight, kg 80.16  16.78 79.04  15.39 78.63  18.09 80.74  22.92
Body mass index, kg/m2 28.62  5.00 26.61  3.97 26.99  4.86 27.55  6.03
Cigarette smoking status
Former 126 (77.30) 45 (75.00) 39 (58.21) 14 (70.00)
Current 37 (22.70) 15 (25.00) 28 (41.79) 6 (30.00)
Pack-years of smoking 27.3 (17.7–42.0) 33.4 (24.5–61.5) 39.0 (25.0–51.3) 44.0 (22.0–62.3)
Blood pressure, mm Hg
Systolic 120.24  19.01 120.47  15.92 123.87  15.94 126.70  12.90
Diastolic 68.82  9.49 70.58  9.02 71.96  9.05 75.68  9.27
Hypertension 70 (42.94) 25 (41.67) 33 (49.25) 8 (40.00)
Fasting plasma glucose, mg/dl 96.0 (91.0–105.0) 95.5 (87.0–107.0) 100.0 (95.0–108.0) 94.0 (84.0–111.5)
Diabetes mellitus 25 (15.34) 5 (8.33) 9 (13.43) 6 (30.00)
Sleep apnea, self-reported 12 (7.36) 4 (6.67) 7 (10.45) 4 (20.00)
Medication use
Inhaled or systemic corticosteroids 2 (1.23) 4 (6.67) 8 (11.94) 15 (75.00)
Beta-agonists 2 (1.23) 5 (8.33) 13 (19.40) 16 (80.00)
Anticholinergics 1 (0.61) 4 (6.67) 8 (11.94) 16 (80.00)
Long-term oxygen therapy 1 (0.61) 0 (0.0) 0 (0.0) 7 (35.00)
Study
MESA 121 (74.23) 29 (48.33) 30 (44.78) 4 (20.00)
EMCAP 41 (25.15) 23 (38.33) 22 (32.84) 4 (20.00)
Community 1 (0.61) 8 (13.33) 15 (22.39) 12 (60.00)
FEV1, % predicted 101.18  15.54 91.77  9.37 69.49  8.18 39.75  6.68
FVC, % predicted 98.17  15.12 106.86  12.27 91.08  12.40 76.56  15.37
FEV1/FVC ratio 0.78  0.05 0.64  0.05 0.58  0.09 0.39  0.08
Percentage of emphysema950 1.17 (0.55–2.27) 3.36 (1.81–7.91) 3.25 (1.13–7.89) 19.92 (7.15–25.90)
Oxygen saturation, % 96.39  2.43 96.00  4.58 96.20  3.84 95.69  1.93
DLCO, % predicted* 68.08  10.50 63.95  11.87 55.12  14.22 38.22  13.01
DLCO/VA, % predicted* 79.36  12.95 69.82  14.87 69.40  19.35 57.34  20.08
Residual volume, % predicted* 86.02  26.28 94.37  18.01 110.94  29.86 149.62  29.93
TLC, % predicted* 98.56  13.38 107.45  10.92 100.58  14.11 104.83  17.27
Residual volume/TLC* 0.31  0.07 0.31  0.05 0.39  0.08 0.50  0.08
Values are mean  SD, n (%), or median (interquartile range). *Assessed for 119 participants at 1 site.
COPD ¼ chronic obstructive pulmonary disease; DLCO ¼ diffusing capacity of the lung for carbon monoxide; FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital
capacity; TLC ¼ total lung capacity; VA ¼ alveolar volume.
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2002(RVEDV) and RV end-systolic volume were calculated
using Simpson’s rule by summation of areas on each
slice multiplied by the sum of slice thickness and
image gap. RV mass was determined at end-diastole
as the difference between end-diastolic epicardialand endocardial volumes multiplied by the speciﬁc
gravity of the heart (1.05 g/cm3). RV stroke volume
was calculated by subtracting RV end-systolic volume
from RVEDV; right ventricular ejection fraction
(RVEF) was calculated by dividing RV stroke volume
TABLE 2 Predicted Mean Values of RV Parameters by COPD Severity
Parameters
COPD
Controls
(n ¼ 163)
Mild
(n ¼ 60)
Moderate
(n ¼ 67)
Severe
(n ¼ 20)
p Value
for Trend
RV end-diastolic volume, ml
Unadjusted mean 130.75 136.08 123.94 118.93
Minimally adjusted* 130.70 129.12 118.40† 106.86† 0.003
Fully adjusted‡ 130.67 129.70 118.94† 107.58† 0.004
RV end-systolic volume, ml
Unadjusted mean 53.64 57.01 52.20 55.86
Minimally adjusted 53.61 51.69 46.98 44.24 0.01
Fully adjusted 53.60 52.06 47.35 44.79 0.06
RV stroke volume, ml
Unadjusted mean 77.11 79.08 71.73 63.06
Minimally adjusted 77.09 77.43 71.42† 62.62† <0.001
Fully adjusted 77.08 77.64 71.60† 62.80† <0.001
RV end-diastolic mass, g
Unadjusted mean 23.01 22.20 20.69 21.71
Minimally adjusted 23.04 22.74 21.66 23.61 0.68
Fully adjusted 23.02 22.90 21.54 23.47 0.55
RV end-diastolic mass/
RV end-diastolic volume
ratio, g/ml
Unadjusted mean 0.18 0.17 0.17 0.22
Minimally adjusted 0.18 0.18 0.19 0.26† 0.03
Fully adjusted 0.15 0.16 0.16 0.23† 0.04
RV ejection fraction, %
Unadjusted mean 59.84 58.97 59.01 55.26
Minimally adjusted 59.84 61.09 61.53 61.02 0.98
Fully adjusted 59.85 60.93 61.38 60.77 0.95
*Adjusted for age, sex, race/ethnicity, height, weight, and cohort. †p < 0.05 versus controls. ‡Adjusted for
variables in minimally adjusted model plus smoking status, pack-years, hypertension, and sleep apnea.
COPD ¼ chronic obstructive pulmonary disease; RV ¼ right ventricular.
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2003by RVEDV. Trabeculations were excluded from RV
mass and included in RV volumes, as in previous
large-scale studies using CMR to assess the ventricles
(27). The RV outﬂow tract was included in the RV
volumes, and the septum was considered part of
the left ventricle for this study (Online Figure 1). Our
method of interpretation has been shown to have
high intra- and inter-reader reproducibility (28).
Pulmonary perfusion was assessed in a subset
of participants (n ¼ 141) using dynamic ﬁrst-pass,
contrast-enhanced CMR of the thorax. Pulmonary
microvascular perfusion was assessed on a coronal
slice at the level of the trachea in the peripheral 2 cm
of the lung, as previously described (29,30).
See the Online Appendix for details of other
pulmonary function measures, the CT and CMR
protocols, and microvascular perfusion measures.
COVARIATES. Age, sex, race/ethnicity, educational
attainment, smoking status, pack-years, and medi-
cal history were self-reported. Medication use
was assessed by medication inventory (31). Height,
weight, and blood pressure were measured following
standardized MESA protocols (25). Participants with a
blood cotinine level >25 ng/ml, a urine level >500
ng/ml, or a self- report of current smoking were
classiﬁed as current smokers. Oxygen saturation was
measured with a pulse oximeter off oxygen, if used.
STATISTICAL ANALYSIS. Data were summarized as
mean  SD or median (interquartile range), as
appropriate. Linear regression models included cate-
gories of COPD status and severity as independent
variables and continuous RV parameters as depen-
dent variables. A test of trend across categories of
COPD severity was performed; if positive, Holm’s
step-down procedure was performed.
Linear regression models also were constructed for
continuous independent variables, weighted accord-
ing to cohort-speciﬁc probabilities of selection and
enrollment into the MESA-COPD study to account
for sampling (32). Robust SEs were used. Results are
shown by quintiles of the percentage of emphysema
for descriptive purposes; statistical tests were based
on the continuous variable in the regression model.
The nonlinearity of these associations was tested in
generalized additive models with the same weighting
and robust SEs.
The minimally adjusted models included age, sex,
height, weight, race/ethnicity, and the cohort from
which the participant was recruited. The fully
adjusted models also included smoking status, pack-
years, hypertension, and sleep apnea (and milliam-
peres for the percentage of emphysema). The full
models were also then adjusted for the respective LVparameters to better understand whether the associ-
ations were right ventricle speciﬁc. There were no
missing covariate data except for 10 participants (3%)
who did not know whether they carried a diagnosis of
sleep apnea; they were assumed not to have sleep
apnea.
The p values were 2-tailed with statistical signiﬁ-
cance deﬁned as p < 0.05. Analyses were performed
with SAS version 9.2 (Cary, North Carolina) and
R version 2.14.1 (Vienna, Austria).
RESULTS
The study enrollment and reasons for exclusion are
shown in Online Figure 2. Of the 310 participants, 47%
had COPD: 60 with mild, 67 with moderate, and 20
with severe disease. The mean age of the participants
was 67.9  7.0 years, 39.7% were women, and 27.7%
were current cigarette smokers. The race/ethnic dis-
tribution was 53.2% non-Hispanic white, 26.1% Afri-
can American, 14.2% Hispanic, and 6.5% Chinese
American.
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FIGURE 1 Multivariate Relationships Between the
FEV1/FVC Ratio and RV End-Diastolic Volume and Mass
Smoothed regression plot of the relationship (solid line) of the
ratio of the FEV1 to FVC with RV end-diastolic volume (A) and
mass (B) and 95% conﬁdence intervals (dashed lines). The plots
were obtained from regression models adjusted for age, sex,
race/ethnicity, cohort, height, weight, smoking status, pack-
years, hypertension, and sleep apnea. The hash marks denote
data points. FEV1 ¼ forced expiratory volume in 1 second;
FVC ¼ forced vital capacity; RV ¼ right ventricular.
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2004Patients with COPD were more likely to be male
and white and somewhat more likely to be current
smokers with more pack-years (Table 1). Those with
COPD demonstrated characteristic spirometric, volu-
metric, and diffusing capacity for carbon monoxide
patterns compared with smoking controls and had
more emphysema. Only 7 of the 147 patients (4.7%)
with COPD used long-term supplemental oxygen
(all of whom had severe COPD).COPD AND THE RIGHT VENTRICLE. RVEDV was
lower in patients with COPD compared with control
subjects (p ¼ 0.02) in minimally adjusted models that
accounted for differences in age, sex, race/ethnicity,
height, weight, and cohort. Results were similar in
fully adjusted models (7.8 ml; 95% conﬁdence
interval: 15.0 to 0.5 ml; p ¼ 0.04).
Increasing severity of COPD was signiﬁcantly
and monotonically associated with lower RVEDV in
minimally and fully adjusted models (Table 2).
The decrement in RVEDV was directly related to the
FEV1/FVC ratio (Figure 1A) without evidence of non-
linearity, such as a J shape (p for nonlinearity ¼ 0.65).
The association of COPD severity with lower RVEDV
persisted after additional adjustment for LV end-
diastolic volume (Online Table 1) (p ¼ 0.02).
A similar association was present for RV end-
systolic volume, although its signiﬁcance was mar-
ginal in the fully adjusted model (Table 2, Online
Table 1). RV stroke volume was signiﬁcantly reduced
with increasing severity of COPD.
RV mass was similar between patients with COPD
and controls in minimally and fully adjusted models
(0.7 g; 95% conﬁdence interval: 2.7 to 1.3; p ¼ 0.51)
and across categories of COPD severity (Table 2,
Online Table 1). There was no evidence of nonline-
arity in the association of the FEV1/FVC ratio and RV
mass (Figure 1B) (p for nonlinearity ¼ 0.13). The ratio
of RV mass to RVEDV was slightly but signiﬁcantly
increased in severe COPD due to reduced volume;
however, RVEF was not associated with the presence
or severity of COPD (Table 2).
The association of RVEDV with COPD was largely
unchanged with 1) further adjustment for long-term
oxygen use, 2) restriction to participants sampled
from MESA and EMCAP or without systemic hyper-
tension, diabetes, or sleep apnea, and 3) stratiﬁcation
by sex (Online Figure 3). There were no differences in
former smokers compared with current smokers (p for
interaction ¼ 0.48), but there may have been a more
pronounced decrement in African-American partici-
pants compared with other race/ethnic groups (p for
interaction ¼ 0.09).
PULMONARY EMPHYSEMA AND THE RIGHT VENTRICLE.
RVEDV was monotonically lower across increasing
categories of percentage of emphysema on CT.
This association was signiﬁcant in minimally and
fully adjusted models (Table 3, Online Table 2) and
was linear (Figure 2A). Increasing percentage of
emphysema was also associated with a signiﬁcantly
lower RV stroke volume. The percentage of emphy-
sema was not associated with RV mass (Figure 2B),
RV mass/RVEDV ratio, or RVEF (Table 3, Online
Table 2).
TABLE 3 Predicted Mean Values for and Differences in RV Parameters by Percentage of Emphysema on Computed Tomography
Percentage of Emphysema Difference per Log
Increase in Percentage
of Emphysema
(95% CI) p Value
Quintile 1
(n ¼ 62)
Quintile 2
(n ¼ 60)
Quintile 3
(n ¼ 62)
Quintile 4
(n ¼ 60)
Quintile 5
(n ¼ 62)
RV end-diastolic volume, ml
Unadjusted mean 128.03 134.34 133.42 131.54 121.89
Minimally adjusted* 134.95 130.63 127.85 124.89 120.41 4.05 (6.90 to 1.21) 0.005
Fully adjusted† 135.22 130.90 128.11 125.15 120.66 4.03 (6.86 to 1.21) 0.005
RV end-systolic volume, ml
Unadjusted mean 53.59 55.99 54.15 55.33 52.81
Minimally adjusted 54.61 53.43 52.67 51.86 50.64 1.10 (3.05 to 0.81) 0.26
Fully adjusted 54.76 53.64 52.92 52.15 50.99 1.03 (2.91 to 0.85) 0.28
RV stroke volume, ml
Unadjusted mean 74.44 78.34 79.27 76.21 69.08
Minimally adjusted 80.36 77.22 75.19 73.04 69.78 2.95 (4.54 to 1.35) <0.001
Fully adjusted 80.45 77.25 75.19 72.99 69.67 3.01 (4.63 to 1.38) <0.001
RV end-diastolic mass, g
Unadjusted mean 21.38 22.28 22.74 22.15 22.78
Minimally adjusted 23.93 23.14 22.64 22.10 21.29 0.73 (1.49 to 0.02) 0.06
Fully adjusted 23.84 23.14 22.69 22.22 21.49 0.65 (1.41 to 0.12) 0.10
RV end-diastolic mass/
RV end-diastolic
volume ratio, g/ml
Unadjusted mean 0.17 0.17 0.17 0.17 0.21
Minimally adjusted 0.18 0.18 0.18 0.18 0.19 0.00 (0.01 to 0.01) 0.57
Fully adjusted 0.18 0.18 0.19 0.19 0.19 0.00 (0.01 to 0.01) 0.47
RV ejection fraction, %
Unadjusted mean 59.43 59.31 59.80 58.43 58.30
Minimally adjusted 60.52 60.00 59.67 59.32 58.78 0.49 (1.28 to 0.31) 0.23
Fully adjusted 60.51 59.93 59.55 59.16 58.55 0.55 (1.34 to 0.24) 0.17
*Adjusted for age, sex, race/ethnicity, height, weight, and cohort. †Adjusted for variables in minimally adjusted model plus smoking status, pack-years, hypertension, sleep
apnea, and high milliampere/second.
CI ¼ conﬁdence interval; RV ¼ right ventricular.
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2005The presence of emphysema assessed by radiolo-
gist interpretation was also associated with lower
RVEDV and RV stroke volume (p ¼ 0.003 and 0.004,
respectively) in fully adjusted models. Whereas cen-
trilobular emphysema and paraseptal emphysema
were signiﬁcantly related to lower RVEDV (p < 0.001
and p ¼ 0.003, respectively), there was no evidence
of such a relationship for panlobular emphysema
(p ¼ 0.39) (Online Table 3).
The ﬁndings for percentage of emphysema and
RVEDV were not sensitive to additional adjustment
or subset analyses (Online Figure 4). We found no
interaction between percentage of emphysema and
smoking status or race in terms of the relationship
with RVEDV (p for interaction ¼ 0.78 and 0.18,
respectively).
OTHER MEASURES . Among participants with
gadolinium-enhanced CMR (n ¼ 141) (Online Table 4),
lower RVEDVs were associated with reduced pulmo-
nary microvascular blood ﬂow and reduced pulmo-
nary microvascular blood volume (Online Table 5).
Higher diffusing capacity for carbon monoxide wasassociated with larger RVEDV, RV end-systolic vol-
ume, and RV stroke volume. We saw no association
between lung volumes and RV parameters (Online
Table 6). Subset analysis with only MESA and
EMCAP participants showed similar results (data not
shown).
For all of the models, we performed routine checks
for model ﬁt to make sure the conclusions were not
based on a few “inﬂuential” subjects. These pro-
cedures provided reassurance that the models had
adequate ﬁt. Adjustment for arterial oxygen satura-
tion by pulse oximetry did not change the results
(data not shown).
DISCUSSION
Patients with COPD displayed, on average, lower
RV volumes compared with control subjects in this
multicenter study that used CMR to assess RV struc-
ture and function. More severe COPD was asso-
ciated with lower RV volumes, but there was no
consistent relationship of COPD severity with RV
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FIGURE 2 Multivariate Relationships Between
Percent Emphysema and RV End-Diastolic Volume andMass
Smoothed regression plot of the relationship (solid line) of
percent emphysema with RV end-diastolic volume (A) and mass
(B) and 95% conﬁdence intervals (dashed lines). The plots were
obtained from regression models adjusted for age, sex, race/
ethnicity, cohort, height, weight, smoking status, pack-years,
hypertension, sleep apnea, and milliampere/second. The hash
marks denote data points. Abbreviations as in Figure 1.
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2006mass. Furthermore, the presence and severity of
emphysema on CT scan were associated with lower
RV volumes and no change in RV mass.
The ﬁnding of reduced RV volumes contradicts the
classic paradigm of cor pulmonale in COPD; that is,
increased RV mass and volume in the setting of lung
disease with or without RV dysfunction (3,33). Our
results for RV volumes are consistent with those of a
recent small study that showed lower RV volumes but
greater RV mass in 25 patients with COPD and mild
hypoxemia (12); other investigations in COPD (allwith <20 patients) have demonstrated similar ﬁnd-
ings (9–11). These studies, however, included only a
few highly select patients and did not adjust for po-
tential confounders, issues that were addressed in
this study.
A previous study in the parent MESA cohort
showed that a greater percentage of emphysema in
the lower two-thirds of the lungs was associated with
lower RV volumes and mass, speciﬁcally in smokers,
with more complicated relationships after adjustment
for the respective LV measures (16). A lower FEV1/FVC
ratio was associated with lower RV mass after
adjustment for LV mass in that study, but in the
current study, increasing COPD severity was linked to
increased RV mass/RVEDV ratio, suggesting increased
RV afterload. However, this association was attribut-
able to lower RVEDV in more severe COPD patients
(rather than increasing RV mass), which is difﬁcult to
attribute to increased RV wall stress.
Our ﬁndings may differ from the traditional mani-
festation of increased RV volumes and increased RV
mass in COPD for several reasons. First, we sampled
participants predominantly from the general popula-
tion, resulting in a sample of patients whose COPD
may be less severe than those in previous studies but
making the results more generalizable. Our sample
size of patients with severe COPD was similar to (or
larger than) those in most previous studies. While
there was a suggestion of a J-shaped relationship of
RV mass with COPD severity, there was no such sug-
gestion for RVEDV or in relation to the percentage of
emphysema. Hence, the disease spectrum alone does
not account for these differences.
Another explanation may be the predominant
COPD subphenotypes studied. Burrows et al. (14)
found that COPD patients with emphysema on chest
radiography were less likely to demonstrate RV hy-
pertrophy on electrocardiography than other COPD
patients, given the same pulmonary vascular resis-
tance. Furthermore, early autopsy studies showed
that patients dying of emphysema did not have evi-
dence of RV hypertrophy, which was more common
in COPD patients with airway inﬂammation and
mucus gland hypertrophy suggestive of chronic
bronchitis (15). More recently, increasing airway wall
size was more strongly associated with increased
pulmonary artery diameter in COPD than was the
percentage of emphysema (34). Other studies of the
“comorbidome” of COPD have suggested that cardiac
complications are linked to more prominent airway
disease and less parenchymal destruction, supporting
a stronger link between the “chronic bronchitis”
subphenotype and traditional cardiac sequelae than
the “emphysema” subphenotype (35,36). We showed
Kawut, S.M., et al., J Am Coll Cardiol. 2014; 64(19):2000–9.
CENTRAL ILLUSTRATION RV and Other Changes in COPD
The potential etiologies of right ventricular changes in patients with COPD.
COPD ¼ chronic obstructive pulmonary disease; RV ¼ right ventricular.
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2007that increasing centrilobular and paraseptal emphy-
sema were associated with lower RV volumes,
whereas panlobular emphysema was not. Therefore,
rather than being inconsistent with the classic para-
digm of cor pulmonale, our ﬁndings may reﬂect the
current phenotype of COPD in the general population
in the United States and may not apply to selected
patients with severe chronic bronchitis or marked gas
trapping.
Consistent with this, Hilde et al. (6) recently pub-
lished a study of Norwegian COPD patients with re-
sidual volume of w200% of predicted normal
undergoing echocardiography and right heart cathe-
terization. These patients demonstrated increased
RV mass (without correction for body size) and more
RV dysfunction compared with smoking controls. In
contrast, patients in our study generally had normal
residual volumes, which were not signiﬁcantly asso-
ciated with RV morphology. The different mix of
subphenotypes of COPD may explain these popula-
tion differences.
Third, treatments for COPD may secondarily affect
afterload and preload and the RV sequelae. Long-
acting bronchodilators reduce hyperinﬂation with
gas trapping and supplemental oxygen could affect
pulmonary vascular disease and RV morphology. We
were not able to test these hypotheses; however, the
very small number of patients in our study receiving
long-acting bronchodilators and oxygen (<5%) and
the persistence of the results despite adjustment for
supplemental oxygen make use of these therapies
unlikely to explain the results.
The mechanism of reduced RV ﬁlling in emphy-
sematous COPD may relate to several factors (Central
Illustration). Watz et al. (7) suggested that pulmonary
hyperinﬂation reduces right atrial and RV ﬁlling in
moderate to severe COPD and lung volume reduction
surgery for very severe COPD (which decreases hy-
perinﬂation) (37,38) is associated with increased
oxygen pulse (39,40), RVEDV, and RV stroke vol-
ume, and reduced atrial pressure (41). However,
measures of hyperinﬂation were not associated with
RV volumes in the current study. Other mechanisms
that reduce blood return to the thorax in severe
COPD, affecting ﬁlling of both ventricles and the
pulmonary vasculature, include a reduced gradient
in pressure between the abdomen and chest and
abnormal diaphragm orientation compressing the
vena cava (42). Alternatively, intrinsic RV diastolic
dysfunction, possibly related to increased inﬂam-
mation or endothelial dysfunction, could decrease
RV ﬁlling (43,44). These novel mechanisms may
suggest innovative approaches that target diastolic
function (e.g., soluble guanylate cyclase activators)to treat the cardiac component of exercise limitation
in these patients.
STUDY LIMITATIONS. Although we included a
modest number of patients with severe COPD, the
ﬁndings appeared to be similar to those with mild and
moderate COPD. We excluded patients with clinically
apparent heart failure, potentially leading to selec-
tion bias. However, the number of participants
excluded for heart failure was very small, lessening
the impact on the results. Assessment of RV
morphology can be challenging due to the presence of
the tricuspid valve; however, previous studies using
the same methodology in our Reading Center have
shown outstanding intra- and inter-reader reliability
for RV measurements. Measurement error (unless
differential by COPD status) would bias to the null, so
that our ﬁndings may underestimate the actual
differences in RV morphology between COPD and
control subjects. The percentage of emphysema
measured quantitatively reﬂects pulmonary emphy-
sema and other factors; nevertheless, radiologist-
determined emphysema showed similar ﬁndings.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: More
severe emphysema in patients with COPD is associ-
ated with smaller RV dimensions.
TRANSLATIONAL OUTLOOK: Further studies are
needed to elucidate the mechanisms by which
changes in right ventricular dimensions and function
are related to the morbidity and mortality associated
with COPD.
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2008We did not acquire invasive hemodynamic measures,
which would be difﬁcult to justify in a large
population-based sample, or transthoracic echocar-
diography, which is technically challenging in pa-
tients with COPD, our main population of study. Our
perfusion measures may have certain technical limi-
tations due to the determination of the arterial input
function and the bolus dose. Although we adjusted
for most potential confounders in multivariate ana-
lyses, residual confounding in multivariable analyses
is possible.
CONCLUSIONS
In the MESA COPD study, more severe COPD and
emphysema on CT were associated with lower RV
volumes without changes in RVEF or RV mass.
Smaller rather than larger RV size appears to be the
more common RV phenotype in COPD in the U.S.
general population without overt cardiovascular dis-
ease, perhaps better termed “cor pulmonale parvus.”
Future studies of COPD treatment should consider
the role of this novel cardiac comorbidity.
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